SlideShare uma empresa Scribd logo
1 de 1
Baixar para ler offline
Vaccine Technology II - Algarve, Portugal 01/06/2008 – 06/06/2008
(Poster Number 19)
COMPARISON OF DENGUE-2 VIRUS PRODUCTION IN VERO CELLS UNDER SERUM-
FREE AND SERUM-CONTAINING CONDITIONS
Érica A. Schulze1,2
, Marta C. Souza2
, Marcos S. Freire2
, Leda R. Castilho3
, Ricardo A. Medronho2
1 Federal University of Rio de Janeiro, School of Chemistry, CT, Bl. E, 21941-909 Rio de Janeiro/RJ, Brazil
2 Bio-Manguinhos/FIOCRUZ, Av. Brasil 4365, 21040-360 Rio de Janeiro/RJ, Brazil
3 Federal University of Rio de Janeiro, COPPE, CT, Bl. G, 21941-914 Rio de Janeiro/RJ, Brazil
The dengue virus belongs to the Flaviviridae family and occurs in 4 different serotypes (dengue-1
to dengue-4). Dengue fever is an emerging disease that has experienced a significant worldwide
increase in incidence in the last years, representing a public health concern in many tropical and
subtropical countries. Among the diseases transmitted by mosquitoes, dengue is currently the
most common worlwide, with approximately 100 million cases every year and a mortality rate of
2.5%. In spite of its impact on public health, no effective vaccine against dengue fever is yet
available on the market.
Vero cells are accepted for the production of human vaccines and are presently used in the
commercial production of different vaccines, such as polio and rabies. However, one of the main
regulatory concerns in this field is related to the use of animal serum and animal-derived
components as culture medium additives. Therefore, in this work we compared the production of
dengue-2 virus (DEN-2) in a serum-containing medium (DMEM + 5% fetal bovine serum) and in a
commercial serum-free medium (VP-SFM, Gibco). A factorial statistical experimental design
methodology was used to evaluate the influence of TOI (1-3 days) and MOI (0.002-0.02) on virus
titer. Experiments were carried out both in T-flasks and in spinner flasks using Cytodex-1
microcarriers, and virus titer was monitored for 7 days post-infection.
The results showed that the influence of MOI and TOI on virus titer varies according to the culture
medium used. In most experiments, DEN-2 virus titer presented an increasing trend in the whole
evaluated period. However, for large MOI values (0.02), a maximum virus production was observed
5 days post-infection in the serum-free medium regardless of the time of infection, and in the
serum-containing medium this peak at 5 dpi occurred only when a large MOI value was combined
with a large TOI (3 days). For the serum-supplemented medium, the maximum virus titer obtained
increased with both MOI and TOI values, whereas for the serum-free medium, virus titer increased
with TOI but remained approximately constant with MOI in the range evaluated in this work. In
general, the use of the serum-supplemented medium gave higher virus production under all
conditions tested. The maximum DEN-2 titer was 4.93E+6 pfu/mL (6.69 in log scale) for the
serum-supplemented DMEM medium, and 1.28E+6 pfu/mL (6.11 in log scale) for the serum-free
VP-SFM medium.

Mais conteúdo relacionado

Mais procurados

Antibacterial properties of venom from three medically important snakes in su...
Antibacterial properties of venom from three medically important snakes in su...Antibacterial properties of venom from three medically important snakes in su...
Antibacterial properties of venom from three medically important snakes in su...ILRI
 
Covid 19 mRNA vaccine platform
Covid 19 mRNA vaccine platformCovid 19 mRNA vaccine platform
Covid 19 mRNA vaccine platformYashfaJavaid
 
Vaccine development for covid 19
Vaccine development for covid 19Vaccine development for covid 19
Vaccine development for covid 19SaptarshiDas78
 
Covid 19 Vaccine Endgame Part I
Covid 19 Vaccine Endgame Part ICovid 19 Vaccine Endgame Part I
Covid 19 Vaccine Endgame Part IA DO
 
Biosciences Nairobi – Spread of tetracycline resistance gene tetM via TN916-l...
Biosciences Nairobi – Spread of tetracycline resistance gene tetM via TN916-l...Biosciences Nairobi – Spread of tetracycline resistance gene tetM via TN916-l...
Biosciences Nairobi – Spread of tetracycline resistance gene tetM via TN916-l...ILRI
 
mRNA Vaccines and HIV
mRNA Vaccines and HIVmRNA Vaccines and HIV
mRNA Vaccines and HIVDhritisdiary
 
Gmo (Genetically Modified Mosquitoes)
Gmo (Genetically Modified Mosquitoes)Gmo (Genetically Modified Mosquitoes)
Gmo (Genetically Modified Mosquitoes)Rajat Basra
 
Manufacturing the COVID-19 Pandemic Vaccine - Group 2
Manufacturing the COVID-19 Pandemic Vaccine - Group 2Manufacturing the COVID-19 Pandemic Vaccine - Group 2
Manufacturing the COVID-19 Pandemic Vaccine - Group 2KuchealArivalagan
 
JSResEssay15-Final-TCDkparsad.doc
JSResEssay15-Final-TCDkparsad.docJSResEssay15-Final-TCDkparsad.doc
JSResEssay15-Final-TCDkparsad.docKanchan Parsad
 
Culturable vs. non culturable
Culturable vs. non culturableCulturable vs. non culturable
Culturable vs. non culturableshantanu pramanik
 
HIV Vaccine Research and HIV drugs in the pipeline HIV Vaccine Research and...
HIV Vaccine Research and HIV drugs in the pipeline 	 HIV Vaccine Research and...HIV Vaccine Research and HIV drugs in the pipeline 	 HIV Vaccine Research and...
HIV Vaccine Research and HIV drugs in the pipeline HIV Vaccine Research and...MedicineAndHealthUSA
 
COVID-19 Developing Vaccinations & Therapeutic Drugs (Update: 15 October 2021)
COVID-19 Developing Vaccinations & Therapeutic Drugs (Update: 15 October 2021)COVID-19 Developing Vaccinations & Therapeutic Drugs (Update: 15 October 2021)
COVID-19 Developing Vaccinations & Therapeutic Drugs (Update: 15 October 2021)Thalassaemia International Federation
 
Mycovirus - A Natural Fungicide
Mycovirus - A Natural FungicideMycovirus - A Natural Fungicide
Mycovirus - A Natural FungicideABHISEK RATH
 

Mais procurados (20)

Antibacterial properties of venom from three medically important snakes in su...
Antibacterial properties of venom from three medically important snakes in su...Antibacterial properties of venom from three medically important snakes in su...
Antibacterial properties of venom from three medically important snakes in su...
 
Covid 19 mRNA vaccine platform
Covid 19 mRNA vaccine platformCovid 19 mRNA vaccine platform
Covid 19 mRNA vaccine platform
 
Vaccine development for covid 19
Vaccine development for covid 19Vaccine development for covid 19
Vaccine development for covid 19
 
Vacunasvet
VacunasvetVacunasvet
Vacunasvet
 
Covid 19 Vaccine Endgame Part I
Covid 19 Vaccine Endgame Part ICovid 19 Vaccine Endgame Part I
Covid 19 Vaccine Endgame Part I
 
Biosciences Nairobi – Spread of tetracycline resistance gene tetM via TN916-l...
Biosciences Nairobi – Spread of tetracycline resistance gene tetM via TN916-l...Biosciences Nairobi – Spread of tetracycline resistance gene tetM via TN916-l...
Biosciences Nairobi – Spread of tetracycline resistance gene tetM via TN916-l...
 
mRNA Vaccines and HIV
mRNA Vaccines and HIVmRNA Vaccines and HIV
mRNA Vaccines and HIV
 
HIV Vaccine
HIV VaccineHIV Vaccine
HIV Vaccine
 
Omicron variant
Omicron variantOmicron variant
Omicron variant
 
Gmo (Genetically Modified Mosquitoes)
Gmo (Genetically Modified Mosquitoes)Gmo (Genetically Modified Mosquitoes)
Gmo (Genetically Modified Mosquitoes)
 
Malarial vaccine
Malarial vaccineMalarial vaccine
Malarial vaccine
 
Manufacturing the COVID-19 Pandemic Vaccine - Group 2
Manufacturing the COVID-19 Pandemic Vaccine - Group 2Manufacturing the COVID-19 Pandemic Vaccine - Group 2
Manufacturing the COVID-19 Pandemic Vaccine - Group 2
 
JSResEssay15-Final-TCDkparsad.doc
JSResEssay15-Final-TCDkparsad.docJSResEssay15-Final-TCDkparsad.doc
JSResEssay15-Final-TCDkparsad.doc
 
Culturable vs. non culturable
Culturable vs. non culturableCulturable vs. non culturable
Culturable vs. non culturable
 
Arntzen
ArntzenArntzen
Arntzen
 
Speaker#2 thomas
Speaker#2 thomasSpeaker#2 thomas
Speaker#2 thomas
 
3.2 eric leroy
3.2 eric leroy3.2 eric leroy
3.2 eric leroy
 
HIV Vaccine Research and HIV drugs in the pipeline HIV Vaccine Research and...
HIV Vaccine Research and HIV drugs in the pipeline 	 HIV Vaccine Research and...HIV Vaccine Research and HIV drugs in the pipeline 	 HIV Vaccine Research and...
HIV Vaccine Research and HIV drugs in the pipeline HIV Vaccine Research and...
 
COVID-19 Developing Vaccinations & Therapeutic Drugs (Update: 15 October 2021)
COVID-19 Developing Vaccinations & Therapeutic Drugs (Update: 15 October 2021)COVID-19 Developing Vaccinations & Therapeutic Drugs (Update: 15 October 2021)
COVID-19 Developing Vaccinations & Therapeutic Drugs (Update: 15 October 2021)
 
Mycovirus - A Natural Fungicide
Mycovirus - A Natural FungicideMycovirus - A Natural Fungicide
Mycovirus - A Natural Fungicide
 

Destaque

Destaque (9)

Rien
RienRien
Rien
 
Concurso Universitario Feria de las Ciencias
Concurso Universitario Feria de las CienciasConcurso Universitario Feria de las Ciencias
Concurso Universitario Feria de las Ciencias
 
Desayunos Europeos
Desayunos EuropeosDesayunos Europeos
Desayunos Europeos
 
Presentación eva
Presentación evaPresentación eva
Presentación eva
 
Informatica
InformaticaInformatica
Informatica
 
C presen (1)
C presen (1)C presen (1)
C presen (1)
 
Claudio
ClaudioClaudio
Claudio
 
O uso dos jogos na educação
O uso dos jogos na educaçãoO uso dos jogos na educação
O uso dos jogos na educação
 
42540043 cerebro-inteligencia-y-emocion-amanda-cespedes-por-io
42540043 cerebro-inteligencia-y-emocion-amanda-cespedes-por-io42540043 cerebro-inteligencia-y-emocion-amanda-cespedes-por-io
42540043 cerebro-inteligencia-y-emocion-amanda-cespedes-por-io
 

Semelhante a COMPARISON OF DENGUE-2 VIRUS PRODUCTION IN VERO CELLS UNDER SERUMFREE AND SERUM-CONTAINING CONDITIONS

Belak thorenleblancviljoenreview2009
Belak thorenleblancviljoenreview2009Belak thorenleblancviljoenreview2009
Belak thorenleblancviljoenreview2009sva-slu_oie-cc
 
Omicron Variant
Omicron Variant Omicron Variant
Omicron Variant Nav Geet
 
Covid-19: state of art at 30.03.2020
Covid-19: state of art at 30.03.2020Covid-19: state of art at 30.03.2020
Covid-19: state of art at 30.03.2020Valentina Corona
 
Natural Approach Targeting Gut Dysbiosis - Hipersensitivity - Inflammation Tr...
Natural Approach Targeting Gut Dysbiosis - Hipersensitivity - Inflammation Tr...Natural Approach Targeting Gut Dysbiosis - Hipersensitivity - Inflammation Tr...
Natural Approach Targeting Gut Dysbiosis - Hipersensitivity - Inflammation Tr...asistenvirtual
 
The study of congenital cytomegalovirus, Rubella and Herpes Simplex Virus-2 i...
The study of congenital cytomegalovirus, Rubella and Herpes Simplex Virus-2 i...The study of congenital cytomegalovirus, Rubella and Herpes Simplex Virus-2 i...
The study of congenital cytomegalovirus, Rubella and Herpes Simplex Virus-2 i...Apollo Hospitals
 
Scientists develop a new sars co v-2 vaccine with the successful experience o...
Scientists develop a new sars co v-2 vaccine with the successful experience o...Scientists develop a new sars co v-2 vaccine with the successful experience o...
Scientists develop a new sars co v-2 vaccine with the successful experience o...DoriaFang
 
Clinical Trials: Phase 1/2 Highlights
Clinical Trials: Phase 1/2 HighlightsClinical Trials: Phase 1/2 Highlights
Clinical Trials: Phase 1/2 HighlightsKumaraguru Veerasamy
 
PRODUCTION OF YELLOW FEVER VIRUS IN VERO CELLS GROWN IN SERUM-FREE MEDIUM
PRODUCTION OF YELLOW FEVER VIRUS IN VERO CELLS GROWN  IN SERUM-FREE MEDIUM PRODUCTION OF YELLOW FEVER VIRUS IN VERO CELLS GROWN  IN SERUM-FREE MEDIUM
PRODUCTION OF YELLOW FEVER VIRUS IN VERO CELLS GROWN IN SERUM-FREE MEDIUM Dr. Érica Schulze
 
10631 artikeltext-38877-1-10-20181022
10631 artikeltext-38877-1-10-2018102210631 artikeltext-38877-1-10-20181022
10631 artikeltext-38877-1-10-20181022Kudzai Mafuwe
 
8 global impact of rv vaccines expt rev vaccines 2010
8 global impact of rv vaccines expt rev vaccines 20108 global impact of rv vaccines expt rev vaccines 2010
8 global impact of rv vaccines expt rev vaccines 2010Ruth Vargas Gonzales
 
2021.04.05.21254934v1.full.pdf
2021.04.05.21254934v1.full.pdf2021.04.05.21254934v1.full.pdf
2021.04.05.21254934v1.full.pdfWagequality
 
“OUTBREAK OF CORONA VIRUS: A DETAILED REVIEW
 “OUTBREAK OF CORONA VIRUS: A DETAILED REVIEW “OUTBREAK OF CORONA VIRUS: A DETAILED REVIEW
“OUTBREAK OF CORONA VIRUS: A DETAILED REVIEWPARUL UNIVERSITY
 
Who 2019-n cov-sci-brief-natural-immunity-2021.1-eng
Who 2019-n cov-sci-brief-natural-immunity-2021.1-engWho 2019-n cov-sci-brief-natural-immunity-2021.1-eng
Who 2019-n cov-sci-brief-natural-immunity-2021.1-engArvinAmores
 
Per contact probability of infection by Highly Pathogenic Avian Influenza
Per contact probability of infection by Highly Pathogenic Avian InfluenzaPer contact probability of infection by Highly Pathogenic Avian Influenza
Per contact probability of infection by Highly Pathogenic Avian InfluenzaHarm Kiezebrink
 
Clinical and evolutionary features of SARS CoV-2 infection (COVID-19) in chil...
Clinical and evolutionary features of SARS CoV-2 infection (COVID-19) in chil...Clinical and evolutionary features of SARS CoV-2 infection (COVID-19) in chil...
Clinical and evolutionary features of SARS CoV-2 infection (COVID-19) in chil...komalicarol
 
Bacteria Isolated From the Cerebrio-Spinal Fluid (Csf) of Suspected Cases of ...
Bacteria Isolated From the Cerebrio-Spinal Fluid (Csf) of Suspected Cases of ...Bacteria Isolated From the Cerebrio-Spinal Fluid (Csf) of Suspected Cases of ...
Bacteria Isolated From the Cerebrio-Spinal Fluid (Csf) of Suspected Cases of ...iosrjce
 
Developing Therapeutic Strategies & Current Knowledge on Drugs For Treatment ...
Developing Therapeutic Strategies & Current Knowledge on Drugs For Treatment ...Developing Therapeutic Strategies & Current Knowledge on Drugs For Treatment ...
Developing Therapeutic Strategies & Current Knowledge on Drugs For Treatment ...LaraV1
 
Rapid diagnosis of drug resistant tuberculosis: current perspectives and chal...
Rapid diagnosis of drug resistant tuberculosis: current perspectives and chal...Rapid diagnosis of drug resistant tuberculosis: current perspectives and chal...
Rapid diagnosis of drug resistant tuberculosis: current perspectives and chal...Dr Muktikesh Dash, MD, PGDFM
 

Semelhante a COMPARISON OF DENGUE-2 VIRUS PRODUCTION IN VERO CELLS UNDER SERUMFREE AND SERUM-CONTAINING CONDITIONS (20)

Belak thorenleblancviljoenreview2009
Belak thorenleblancviljoenreview2009Belak thorenleblancviljoenreview2009
Belak thorenleblancviljoenreview2009
 
Omicron Variant
Omicron Variant Omicron Variant
Omicron Variant
 
dengue fever management
dengue fever management  dengue fever management
dengue fever management
 
Covid-19: state of art at 30.03.2020
Covid-19: state of art at 30.03.2020Covid-19: state of art at 30.03.2020
Covid-19: state of art at 30.03.2020
 
Natural Approach Targeting Gut Dysbiosis - Hipersensitivity - Inflammation Tr...
Natural Approach Targeting Gut Dysbiosis - Hipersensitivity - Inflammation Tr...Natural Approach Targeting Gut Dysbiosis - Hipersensitivity - Inflammation Tr...
Natural Approach Targeting Gut Dysbiosis - Hipersensitivity - Inflammation Tr...
 
The study of congenital cytomegalovirus, Rubella and Herpes Simplex Virus-2 i...
The study of congenital cytomegalovirus, Rubella and Herpes Simplex Virus-2 i...The study of congenital cytomegalovirus, Rubella and Herpes Simplex Virus-2 i...
The study of congenital cytomegalovirus, Rubella and Herpes Simplex Virus-2 i...
 
Scientists develop a new sars co v-2 vaccine with the successful experience o...
Scientists develop a new sars co v-2 vaccine with the successful experience o...Scientists develop a new sars co v-2 vaccine with the successful experience o...
Scientists develop a new sars co v-2 vaccine with the successful experience o...
 
Clinical Trials: Phase 1/2 Highlights
Clinical Trials: Phase 1/2 HighlightsClinical Trials: Phase 1/2 Highlights
Clinical Trials: Phase 1/2 Highlights
 
PRODUCTION OF YELLOW FEVER VIRUS IN VERO CELLS GROWN IN SERUM-FREE MEDIUM
PRODUCTION OF YELLOW FEVER VIRUS IN VERO CELLS GROWN  IN SERUM-FREE MEDIUM PRODUCTION OF YELLOW FEVER VIRUS IN VERO CELLS GROWN  IN SERUM-FREE MEDIUM
PRODUCTION OF YELLOW FEVER VIRUS IN VERO CELLS GROWN IN SERUM-FREE MEDIUM
 
10631 artikeltext-38877-1-10-20181022
10631 artikeltext-38877-1-10-2018102210631 artikeltext-38877-1-10-20181022
10631 artikeltext-38877-1-10-20181022
 
COVID-19 variant OMICRON
COVID-19 variant OMICRONCOVID-19 variant OMICRON
COVID-19 variant OMICRON
 
8 global impact of rv vaccines expt rev vaccines 2010
8 global impact of rv vaccines expt rev vaccines 20108 global impact of rv vaccines expt rev vaccines 2010
8 global impact of rv vaccines expt rev vaccines 2010
 
2021.04.05.21254934v1.full.pdf
2021.04.05.21254934v1.full.pdf2021.04.05.21254934v1.full.pdf
2021.04.05.21254934v1.full.pdf
 
“OUTBREAK OF CORONA VIRUS: A DETAILED REVIEW
 “OUTBREAK OF CORONA VIRUS: A DETAILED REVIEW “OUTBREAK OF CORONA VIRUS: A DETAILED REVIEW
“OUTBREAK OF CORONA VIRUS: A DETAILED REVIEW
 
Who 2019-n cov-sci-brief-natural-immunity-2021.1-eng
Who 2019-n cov-sci-brief-natural-immunity-2021.1-engWho 2019-n cov-sci-brief-natural-immunity-2021.1-eng
Who 2019-n cov-sci-brief-natural-immunity-2021.1-eng
 
Per contact probability of infection by Highly Pathogenic Avian Influenza
Per contact probability of infection by Highly Pathogenic Avian InfluenzaPer contact probability of infection by Highly Pathogenic Avian Influenza
Per contact probability of infection by Highly Pathogenic Avian Influenza
 
Clinical and evolutionary features of SARS CoV-2 infection (COVID-19) in chil...
Clinical and evolutionary features of SARS CoV-2 infection (COVID-19) in chil...Clinical and evolutionary features of SARS CoV-2 infection (COVID-19) in chil...
Clinical and evolutionary features of SARS CoV-2 infection (COVID-19) in chil...
 
Bacteria Isolated From the Cerebrio-Spinal Fluid (Csf) of Suspected Cases of ...
Bacteria Isolated From the Cerebrio-Spinal Fluid (Csf) of Suspected Cases of ...Bacteria Isolated From the Cerebrio-Spinal Fluid (Csf) of Suspected Cases of ...
Bacteria Isolated From the Cerebrio-Spinal Fluid (Csf) of Suspected Cases of ...
 
Developing Therapeutic Strategies & Current Knowledge on Drugs For Treatment ...
Developing Therapeutic Strategies & Current Knowledge on Drugs For Treatment ...Developing Therapeutic Strategies & Current Knowledge on Drugs For Treatment ...
Developing Therapeutic Strategies & Current Knowledge on Drugs For Treatment ...
 
Rapid diagnosis of drug resistant tuberculosis: current perspectives and chal...
Rapid diagnosis of drug resistant tuberculosis: current perspectives and chal...Rapid diagnosis of drug resistant tuberculosis: current perspectives and chal...
Rapid diagnosis of drug resistant tuberculosis: current perspectives and chal...
 

COMPARISON OF DENGUE-2 VIRUS PRODUCTION IN VERO CELLS UNDER SERUMFREE AND SERUM-CONTAINING CONDITIONS

  • 1. Vaccine Technology II - Algarve, Portugal 01/06/2008 – 06/06/2008 (Poster Number 19) COMPARISON OF DENGUE-2 VIRUS PRODUCTION IN VERO CELLS UNDER SERUM- FREE AND SERUM-CONTAINING CONDITIONS Érica A. Schulze1,2 , Marta C. Souza2 , Marcos S. Freire2 , Leda R. Castilho3 , Ricardo A. Medronho2 1 Federal University of Rio de Janeiro, School of Chemistry, CT, Bl. E, 21941-909 Rio de Janeiro/RJ, Brazil 2 Bio-Manguinhos/FIOCRUZ, Av. Brasil 4365, 21040-360 Rio de Janeiro/RJ, Brazil 3 Federal University of Rio de Janeiro, COPPE, CT, Bl. G, 21941-914 Rio de Janeiro/RJ, Brazil The dengue virus belongs to the Flaviviridae family and occurs in 4 different serotypes (dengue-1 to dengue-4). Dengue fever is an emerging disease that has experienced a significant worldwide increase in incidence in the last years, representing a public health concern in many tropical and subtropical countries. Among the diseases transmitted by mosquitoes, dengue is currently the most common worlwide, with approximately 100 million cases every year and a mortality rate of 2.5%. In spite of its impact on public health, no effective vaccine against dengue fever is yet available on the market. Vero cells are accepted for the production of human vaccines and are presently used in the commercial production of different vaccines, such as polio and rabies. However, one of the main regulatory concerns in this field is related to the use of animal serum and animal-derived components as culture medium additives. Therefore, in this work we compared the production of dengue-2 virus (DEN-2) in a serum-containing medium (DMEM + 5% fetal bovine serum) and in a commercial serum-free medium (VP-SFM, Gibco). A factorial statistical experimental design methodology was used to evaluate the influence of TOI (1-3 days) and MOI (0.002-0.02) on virus titer. Experiments were carried out both in T-flasks and in spinner flasks using Cytodex-1 microcarriers, and virus titer was monitored for 7 days post-infection. The results showed that the influence of MOI and TOI on virus titer varies according to the culture medium used. In most experiments, DEN-2 virus titer presented an increasing trend in the whole evaluated period. However, for large MOI values (0.02), a maximum virus production was observed 5 days post-infection in the serum-free medium regardless of the time of infection, and in the serum-containing medium this peak at 5 dpi occurred only when a large MOI value was combined with a large TOI (3 days). For the serum-supplemented medium, the maximum virus titer obtained increased with both MOI and TOI values, whereas for the serum-free medium, virus titer increased with TOI but remained approximately constant with MOI in the range evaluated in this work. In general, the use of the serum-supplemented medium gave higher virus production under all conditions tested. The maximum DEN-2 titer was 4.93E+6 pfu/mL (6.69 in log scale) for the serum-supplemented DMEM medium, and 1.28E+6 pfu/mL (6.11 in log scale) for the serum-free VP-SFM medium.